EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis
Links shared publicly online about this topic.
- 469total visits
EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS).
View full resource at news-medical.net
Tags: Multiple Sclerosis, Diet and Nutrition, Drug, FDA, Merck & Co., Merck KGaA, Oncology, News
Most Recently Shared on March 2, 2011 at 10:55 am By:
Oncology News: EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis:... http://bit.ly/eokKUi
Advertisement
